Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2026-01-06 00:00:00 ET · period of report 2025-12-31 · accession 0001628280-26-000964 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-06 | 2025-12-31 | PCRX | Teehan Brendan | Chief Commercial Off | A - Grant | $10.76 | +402.27 | 54.4K | +0.7% | +$4,328 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | A | A | 402.27 | $10.76 | 54,402.27 | D | — | — | (F1) Represents shares of common stock acquired under the issuer's employee stock purchase plan in December 2025. |